Lyell Immunopharma (LYEL) Earnings Date & Reports

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LYEL is expected to report earnings to rise 7.29% to -205 cents per share on November 10

Lyell Immunopharma LYEL Stock Earnings Reports

Q3'26

Est.

$-2.06

Q2'26

Beat

by $0.22

Q1'26

Missed

by $0.92

Q4'25

Missed

by $6.69

Q3'25

Missed

by $1.96

The last earnings report on August 12 showed earnings per share of -191 cents, beating the estimate of -214 cents. With 37.46K shares outstanding, the current market capitalization sits at 315.87M.

View a ticker or compare two or three

LYEL

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for LYEL